Request Appointment
1500 Duarte RdDuarte, CA 91010
Fax+1 314-362-6959
Overview of Dr. Goldsmith
Dr. Scott Goldsmith is a hematologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from University of Florida College of Medicine and has been in practice 4 years. He specializes in hematologic oncology. He has more than 30 publications and over 450 citings.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2013 - 2016
University of Florida College of MedicineClass of 2013
Certifications & Licensure
CA State Medical License 2021 - 2027
MO State Medical License 2015 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Nov 22
- A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2022 May 31
Publications & Presentations
PubMed
- 1 citationsA phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma.Scott R Goldsmith, Michael J Slade, Mark Fiala, Melinda Harding, Zachary D Crees
Annals of Hematology. 2024-11-01 - 4 citationsClonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy.Scott R Goldsmith, Geoffrey Shouse, F Lennie Wong, Alysia Bosworth, Aleksi Iukuridze
Transplantation and Cellular Therapy. 2024-09-01 - 1 citationsAbsolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.Jack Khouri, Danai Dima, Hong Li, Doris Hansen, Surbhi Sidana
Transplantation and Cellular Therapy. 2024-08-01
Abstracts/Posters
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple MyelomaScott R. Goldsmith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Ire of IRE1_: Overexpression of IRE1_ at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1_ Expression Is Predictive of Therapy ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
